Palisade Bio, Inc.: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's ...
The Manila Times

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s ...

Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the ...

Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® ...
MedCity News

Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition

Eli Lilly is building its prospects in immunology through the $1.2 billion acquisition of Ventyx Biosciences, a clinical-stage company with drugs addressing a promising target offering the potential ...
TMCnet

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD ...
FierceBiotech

AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
MedCity News

Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials

For a plaque psoriasis drug to succeed in a clinical trial, it doesn’t need to clear all of the redness and other signs of the inflammatory skin disease. But complete skin clearance is a benchmark ...
Nature

Anti-nausea drug could be used against drug-resistant TB

A radical strategy to tackle drug-resistant tuberculosis could involve reprogramming the metabolism of immune cells called macrophages. This approach makes the bacteria they harbour more sensitive to ...
BioSpace

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...
Monthly Prescribing Reference

Roflumilast Cream 0.3% Under Review for Younger Patients With Plaque Psoriasis

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...
MedPage Today

GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...